Dr. Galbraith Discusses the Development of AZD9291

Video

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.

AZD9291 is a selective, irreversible inhibitor targeting EGFR activating and resistance mutations in lung cancer. A significant proportion of patients with lung cancer have an EGFR mutation: about 15% in the West and 30-40% in Asia. Though most can be treated with erlotinib or gefitinib, 60% of patients develop resistance. AZD9291 hits both the activating and resistance (T790M) mutations, Galbraith says.

In this analysis of over 200 patients with the T790M mutation who have been previously treated with an EGFR inhibitor, the response rate to AZD9291 was about 64% and the progression-free survival curves were encouraging. This drug was also designed to overcome the side effects of early EGFR inhibitors, Galbraith says, and was generally well tolerated.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,